Dan Stanton, Managing editor

March 30, 2021

In the latest episode of the BioProcess Insider Expression Platform, Thermo Fisher Scientific’s Vincenza Pironti discusses how vaccine and biologic makers can ensure a robust, global fill/finish supply both during the COVID pandemic and beyond.

Vincenza Pironti – Global SME, Steriles, ThermoFisher Scientific – sat down (at a distance) with editor Dan Stanton to discuss aseptic manufacturing in the current climate as part of this year’s BIO-Europe Spring.

The event took place last week, but if you missed it the conversation has been captured in the latest epsiode in our podcast series.

Listen below, Google, ITunes, or wherever you get your podcasts.

 

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.


From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like